Home › Compare › BOMXF vs ABBV
BOMXF yields 4.99% · ABBV yields 3.06%● Live data
📍 BOMXF pulled ahead of the other in Year 5
Combined, BOMXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BOMXF + ABBV for your $10,000?
Bolsa Mexicana de Valores, S.A.B. de C.V. operates cash, listed derivatives, and OTC markets for various asset classes, including equities, fixed income, and exchange traded funds. The company also provides custody, clearing and settlement facilities, and data products for the local and international financial community. It operates the Mexican Stock Exchange that provides facilities and mechanisms as an aid in the relationship of the securities supply and demand, credit certificates, and other documents registered at the National Securities Registry, as well as services for underwriting, offering, and the exchange of the aforementioned securities; and publishes, provides, and maintains information of the securities listed at the Mexican Exchange and at the International Quotations System to the general public. The company's exchange also issues regulation that sets standards, and operative and conduct guidelines to promote fair and equitable market practices at the securities market; and guards its observation and impose disciplinary and corrective measures in case of lack of fulfillment for brokerage firms and the issuers with listed securities at the Mexican Exchange. In addition, it offers central securities depository, custody and settlement of securities, clearing house, price valuation, and risk management services. The company is based in Mexico City, Mexico.
Full BOMXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.